Valion Bio, Inc. (VBIO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+868.4%

$5.14

vs $0.53 price

Levered DCF

$5.36

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-4.49

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
P/E	-4.62×	-7.48×	-4.33×	-15.38×	-39.89×	-330.36×	-289.81×
P/B	2.49×	16.68×	9.97×	42.62×	25.52×	-1,021.35×	507.02×
P/S	0×	0×	30.35×	84.09×	269.45×	1,397.83×	2,862.22×
EV / EBITDA	-4.55×	-9.91×	-4.05×	-15.29×	-58.2×	-362.98×	-329.71×
Gross margin	0.0%	0.0%	24.4%	16.3%	-3.7%	-27.1%	-69.8%
Operating margin	0.0%	0.0%	-701.1%	-548.8%	-448.1%	-386.2%	-867.4%
Net margin	0.0%	0.0%	-701.0%	-548.7%	-675.7%	-423.1%	-987.6%
Current ratio	20.13×	9.7×	3.32×	2.83×	11.72×	1.17×	4.55×
Debt / equity	0.38×	0×	0.1×	0.15×	0.05×	-1.25×	0×
Interest coverage	-54.1×	0×	0×	0×	-3.09×	-7.85×	-8.22×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Return on equity	-52.9%	-223.1%	-230.3%	-278.1%	-64.0%	309.2%	-174.9%
Return on invested capital	-25.5%	-174.2%	-208.8%	-242.7%	-40.3%	-1137.3%	-153.6%
Return on assets	-28.1%	-201.5%	-159.9%	-171.8%	-56.5%	-237.7%	-137.2%
Free cash flow yield	-16.8%	-13.5%	-24.2%	-5.8%	-1.7%	-0.3%	-0.3%
Earnings yield	-21.2%	-13.4%	-23.1%	-6.5%	-2.5%	-0.3%	-0.3%
Enterprise value	$35.7M	$40.3M	$32.7M	$151.7M	$326.4M	$1.2B	$1.2B
Net debt / EBITDA	0.79×	0.49×	0.38×	0.3×	2.19×	-0.13×	0.64×
Cash conversion cycle (days)	0	201	72	-88	-74	-21	66